FOCUSE - The Swedish Precision Cancer Medicine Trial

FOCUSE is an initiative by Testbed Sweden Precision Health Cancer, founded by Vision Zero Cancer, Genomic Medicine Sweden and SciLifeLab, involving regulators, policymakers, payers, researchers, healthcare providers, patient advocates, and industry to drive the implementation of precision health in cancer care.

Enhance advanced cancer care in Sweden with a nationwide Precision Cancer Medicine trial.

The upcoming trial, inspired by the Drug Rediscovery Protocol (DRUP) family of trials, utilizes a prospective, non-randomized Simon two-stage design. Patients are selected based on thorough molecular profiling and closely monitored for residual disease.

Building on Swedish expertise in multi-omics and drug sensitivity screening, we aim to discover novel predictive biomarkers and therapeutic targets, leading the way for the next generation of precision medicine and improving clinical outcomes.